0001562180-21-001781.txt : 20210302
0001562180-21-001781.hdr.sgml : 20210302
20210302160649
ACCESSION NUMBER: 0001562180-21-001781
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210226
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burke Steven Keith
CENTRAL INDEX KEY: 0001619834
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 21703567
MAIL ADDRESS:
STREET 1: 82 WILLIS ROAD
CITY: SUDBURY
STATE: MA
ZIP: 01776
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-02-26
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001619834
Burke Steven Keith
C/O AKEBIA THERAPEUTICS, INC
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, Chief Medical Officer
Common Stock
2021-02-26
4
A
false
70000.00
0.00
A
169000.00
D
Common Stock
2021-03-01
4
S
false
7558.00
3.3961
D
161442.00
D
Employee Stock Option (Right to buy)
3.46
2021-02-26
4
A
false
120000.00
0.00
A
2031-02-26
Common Stock
120000.00
120000.00
D
The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
/s/ Andrea J. Paul, attorney-in-fact for Steven K. Burke
2021-03-02
EX-24
2
poasburke_aug2020.txt
POA UPDATED AUG '20
POWER OF ATTORNEY
Know all by these present, that the undersigned hereby
constitutes and appoints each of John P. Butler, David A. Spellman,
Nicole R. Hadas, Kristie Wagner and Andrea J. Paul signing singly,
as the undersigneds true and lawful attorney-in-fact to:
(1) prepare, execute in the undersigneds
name and on the undersigneds behalf, and
submit to the U.S. Securities and Exchange Commission (the SEC)
a Form ID, including amendments thereto, and any other documents
necessary or appropriate to obtain codes and passwords enabling
the undersigned to make electronic filings with the SEC of reports
required by Section 16(a) of the Securities Exchange Act of 1934,
as amended (the Act) or any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned, in
the undersigneds capacity as an officer, director and/or
shareholder of Akebia Therapeutics, Inc. (the Company),
Forms 3, 4 and 5 in accordance with Section 16(a) of the Act,
and the rules thereunder, or Forms 144 in accordance with Rule 144
under the Securities Act of 1933, as amended (Rule 144);
(3) do and perform any and all acts for and on behalf
of the undersigned that may be necessary or desirable to complete
and execute any such Form 3, 4 or 5 or Form 144, and timely file such form with
the SEC and any stock exchange or similar authority; and
(4) take any other action of any type whatsoever in
connection with the foregoing that, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of, or
legally required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form
and shall contain such terms and conditions as such attorney-in-fact
may approve in such attorney-in-facts discretion.
The undersigned hereby grants to each attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents
and purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and
confirming all the acts such attorney-in-fact shall lawfully do or
cause to be done by virtue of this Power of Attorney and the rights
and powers herein granted. The undersigned acknowledges that each of
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, is not assuming any of the undersigneds
responsibilities to comply with Section 16 of the Act or Rule 144.
This Power of Attorney supersedes any power of attorney previously
executed by the undersigned regarding the purposes outlined in the first
paragraph hereof. This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5, or
Forms 144, with respect to the undersigneds holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to each of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of August 12, 2020.
By:
/s/ Steven Burke
Name:
Steven Burke